Synergistic effects of the combined treatment of U251 and T98G glioma cells with an anti‑tubulin tetrahydrothieno[2,3‑c]pyridine derivative and a peptide nucleic acid targeting miR‑221‑3p

Int J Oncol. 2021 Aug;59(2):61. doi: 10.3892/ijo.2021.5241. Epub 2021 Jul 19.

Abstract

In the development of novel and more effective anticancer approaches, combined treatments appear to be of great interest, based on the possibility of obtaining relevant biological or therapeutic effects using lower concentrations of single drugs. Combination therapy may prove to be of utmost significance in the management of glioblastoma (GBM), a lethal malignancy that accounts for 42% of cancer cases of the central nervous system, with a median survival rate of 15 months. As regards novel therapeutic approaches, the authors have recently demonstrated that peptide nucleic acids (PNAs) that target microRNA (miRNA/miR)‑221 are very active in inducing the apoptosis of glioma cells. Furthermore, in a recent study, the authors described two novel series of tubulin polymerization inhibitors based on the 4,5,6,7‑tetrahydrothieno[2,3‑c]pyridine and 4,5,6,7‑tetrahydrobenzo[b]thiophene scaffold, which exerted a potent anti‑proliferative effect on a variety of tumor cell lines. The present study aimed to verify the activity on glioblastoma cancer cell lines of one of the most active compounds tested, corresponding to 2‑(3', 4', 5'‑trimethoxyanilino)‑3‑cyano/alkoxycarbonyl‑6‑substituted‑4 5,6,7‑tetrahydrothiene[2,3‑c] pyridine (compound 3b), used in combination with an anti‑miR‑221‑3p PNA, already demonstrated to be able to induce high levels of apoptosis. To the best of our knowledge, the results obtained herein demonstrate for the first time a 'combination therapy' performed by the combined use of a PNA targeting miR‑221 and the tetrahydrothiene[2,3‑c]pyridine derivative 3b, supporting the concept that the combined treatment of GBM cells with a PNA against a specific upregulated oncomiRNA (in the present study a PNA targeting miR‑221‑3p was used) and anti‑tubulin agents (in the present study derivative 3b was used) is an encouraging strategy which may be used to enhance the efficacy of anticancer therapies and at the same time, to reduce side‑effects.

Keywords: 3‑c]pyridine; anti‑miR; apoptosis; cell cycle; combination therapy; glioma; miR‑221; microRNA; peptide nucleic acid; tetrahydrothieno[2; tubulin.

MeSH terms

  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / genetics*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Drug Synergism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Glioma / drug therapy
  • Glioma / genetics*
  • Humans
  • MicroRNAs / genetics*
  • Peptide Nucleic Acids / pharmacology*
  • Pyridines / pharmacology*
  • Tubulin Modulators / pharmacology*
  • Up-Regulation / drug effects

Substances

  • MIRN221 microRNA, human
  • MicroRNAs
  • Peptide Nucleic Acids
  • Pyridines
  • Tubulin Modulators

Grants and funding

The authors wish to thank the 'Associazione Tutti per Chiara' (Montagnana, Italy) and AIRC/FIRC for supporting MZ and JG, respectively with research fellowships. The present study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) (IG #13575 to RG), FAR (University Fund for Scientific Research) and FIR (University Fund for the Incentivation of Research). The present study was also supported by the European Union (EU) Horizon 2020 Research and Innovation Programme [GA #633937, project ULTRAsensitive PLAsmonic devices for early CAncer Diagnosis (ULTRAPLACAD)] and by the Interuniversity Consortium for the Biotechnology, Italy.